Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
Subscribe to see Picard Medical, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Picard Medical, Inc. is a medical devices company headquartered in Tucson, United States. It is publicly listed (PMI) with a market capitalisation of $36.1M. Xcout tracks 14 named people at Picard Medical, Inc., including Yuncai Fang (Interim CEO & Chairman of the Board).
8 more named people on record for Picard Medical, Inc., with roles, board committees and tenure — see the full roster →
3 corporate events on record, with sources — see the full timeline →
A few of Picard Medical, Inc.'s closest competitors — see the full list of competitors and alternatives →
BiVACOR, Inc. is a clinical-stage medical device company founded in 2008 that pioneers the development of a total artificial heart to replace failing hearts and restore patient lives. The company is headquartered in Huntington Beach, California, with clinical offices in Houston, Texas, and international facilities in Australia.
Procyrion, Inc. is a Houston, Texas-based heart pump developer. The company focuses on the research, expansion, and development of its Aortix circulatory support device for investigational use.
Corvion Inc., formerly known as EverHeart Systems, is headquartered in Webster, Texas, and develops fully implanted mechanical circulatory support devices. Its flagship product, the Corvion LVAD, is designed to serve as a successful circulatory support device for severe heart failure.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Picard Medical, Inc.? Suggest a correction
Post the link and the card appears automatically — each network fetches the image itself.